Literature DB >> 7835774

Hard choices: the gynecologic cancer patient's end-of-life preferences.

D Brown1, J A Roberts, T E Elkins, D Larson, M Hopkins.   

Abstract

Few reports in gynecologic literature have addressed patient preferences about terminal care. In light of the current discussions about end-of-life decision-making, a study was designed to assess the desires of patients with gynecologic cancer. A questionnaire was completed by 108 patients under treatment for gynecologic cancer at the University of Michigan Medical Center and by 39 patients from the routine gynecology clinic at the same institution. Participants were asked about their reactions to a poor prognosis, their desires for the location of terminal care, and their preferences for withdrawing or withholding life-sustaining technologies. Five percent of these cancer patients anticipated giving up the fight against their disease. Seventy-eight percent specifically expressed resolve to continue the fight against their disease. Feedback from these patients about their end-of-life preferences served to define the concept "fight." A majority preferred to receive care at home. Ninety percent of these cancer patients could envision their conditions deteriorating to the point that they would not want ventilator support. Thirty-four percent could envision refusing surgery for another life-threatening condition; 37%, a time when artificial nutrition would be refused; 22%, a time when antibiotics would be rejected. This study suggests that limiting the use of artificial respiratory support while continuing the use of artificial nutrition and hydration support would be consistent with the preferences of gynecologic cancer with end-stage disease.

Entities:  

Keywords:  Death and Euthanasia; Empirical Approach; University of Michigan Medical Center

Mesh:

Year:  1994        PMID: 7835774     DOI: 10.1006/gyno.1994.1306

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  2 in total

1.  Views of patients with gynecologic cancer about the end of life.

Authors:  Nezihe Kizilkaya Beji; Nesrin Reis; Beyhan Bag
Journal:  Support Care Cancer       Date:  2005-02-08       Impact factor: 3.603

Review 2.  Measuring Quality of Life in Ovarian Cancer Clinical Trials-Can We Improve Objectivity and Cross Trial Comparisons?

Authors:  Gita Bhat; Katherine Karakasis; Amit M Oza
Journal:  Cancers (Basel)       Date:  2020-11-07       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.